The results of this study were independent of whether MET positivity by immunohistochemistry was determined using an H-score cutoff of 300 or at least 200.
For patients with advanced lung cancer characterized by an EGFR-activating mutation that has progressed on osimertinib, treatment decision making is challenging.
303 the number needed to screen in extended follow-up of National Lung Screening Trial.
Higher rate of treatment failure for lung cancer patients with high Deep Profiler scores.
Researchers retrospectively assessed the relationship between tumor mutation burden and specific EGFR alterations.
Combination of clinical and radiologic factors can reliably predict risk for incident lung cancer.
Patients with lung cancer who were treated with immune checkpoint inhibitors had worse outcomes if they received corticosteroids for palliative indications.
In this patient subset, BEV+PEM maintenance therapy after CAR+PEM+BEV induction therapy “could have survival benefits.”
The approval was based on data from 83 patients with SCLC who were enrolled in either the KEYNOTE-028 or KEYNOTE-158 trials.
Cardiac radiation dose exposure is a modifiable cardiac risk factor for major adverse cardiac events (MACE) and all-cause mortality (ACM) in patients with non-small cell lung cancer (NSCLC).
Adding pemetrexed-carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but also increased toxicity.
RELAY is a multicenter, double-blind, randomized clinical trial that enrolledin patients who had no prior treatment for 1L epidermal growth factor receptor (EGFR)-mutant metastatic non−small cell lung cancer.
During 2013, only 4.9% of older patients with the specified solid tumor cancers received chemotherapy within the last 14 days of life.
Deep learning, a subset of artificial intelligence, may mitigate the risks of lung cancer screening with low-dose computed tomography.
In this study, higher levels of tumor PD-L1 expression correlated with higher responses to neoadjuvant immune checkpoint inhibitor-based therapy.
The primary end point of the study is the percentage of patients achieving a major pathological response.
A FAERS analysis demonstrated that osimertinib is associated with increased odds of developing cardiotoxicities compared with other EGFR TKIs.
Among those who had not received prior treatment, overall survival was 23.2% after 5 years.
The addition of metformin to curative chemoradiation therapy was well tolerated in patients with unresected stage IIIA/B NSCLC.
The identification of biomarkers of response and resistance to immune checkpoint inhibitors remains an active area of research.